Health · FDA
FDA Approves Regeneron’s Livsayis, First siRNA Drug for Myasthenia Gravis
The quarterly injection is for adults with the antibody-positive form of the muscle-weakness disease and carries a boxed warning for meningococcal infection.

The Food and Drug Administration on Nov. 18 approved Regeneron’s Livsayis (cemdisiran) for adults with generalized myasthenia gravis who test positive for antibodies to the acetylcholine receptor, AJMC and Pharmaceutical Executive reported, citing the company. Both describe it as the first approved therapy of its kind, a small interfering RNA that lowers the complement protein C5. It is given by injection under the skin every three months by a health care provider.
In the phase 3 NIMBLE trial, patients on cemdisiran improved by 4.5 points on a patient-reported daily-living scale at week 24, against 2.2 points for placebo, according to both outlets. A clinician-rated scale showed gains of 4.2 points versus 1.5. Adding a second drug did not improve results.
The drug’s label includes the agency’s strictest warning, about dangerous meningococcal infections. Vaccination is advised no later than two weeks ahead of the first dose, barring urgent need, and the drug is available only through a restricted safety program. Frequent side effects included reactions where the shot is given, plus viral and urinary tract infections.
The outlets did not report a price or U.S. launch date. AJMC said Regeneron estimates about 85,000 U.S. patients have the condition. Both outlets rely on Regeneron’s announcement, and the FDA’s own notice was not reviewed.
Sources
- AJMC, Nov. 19, 2026, Giuliana Grossi: approval, dosing, NIMBLE results, boxed warning, patient estimate <https://www.ajmc.com/view/fda-approves-first-sirna-therapy-for-achr-positive-myasthenia-gravis>
- Pharmaceutical Executive, Nov. 19, 2026: indication, trial design, safety program, no price or launch date <https://www.pharmexec.com/view/fda-approves-livsayis-first-sirna-therapy-myasthenia-gravis>
This article was drafted with AI writing tools from the sources listed, checked by a review pass, supervised by the paper’s editors and published by Daniel Varrone. Corrections: editor@monochromechronicles.com
More from Health
Recommended Reading
About this story: Compiled by the The Monochrome Chronicles desk from the sources listed above. Our standards · Report an error · Follow on YouTube